Project Grant R21CA303454
Award Date 9/5/25
Completion Date 8/31/27
Dollars Obligated $396K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
- This $640,135 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a new generation of potent menin inhibitors that can overcome resistance observed in current menin inhibitor treatments for acute myeloid leukemia (AML) patients. The award recipient, the Regents of the University of Michigan, will leverage its expertise in medicinal chemistry and cancer biology to design and test these next-generation menin...
- This Project Grant award of $549,474, provided by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395), aims to identify and validate specific inhibitors of the enzyme phosphoribosylformylglycinamidine synthase (PFAS) as a new class of purine antimetabolites for cancer treatment. The research seeks to address a fundamental gap in understanding how PFAS contributes to the progression of liver cancer, with the long-term goal of developing new...
- This federal Project Grant award for $394,532, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research to evaluate the therapeutic potential of targeting the amino acid transporter LAT1 in colorectal cancer. The research aims to investigate how LAT1 inhibition can reduce tumor growth and enhance antitumor immune responses, with the goal of improving treatment outcomes for patients with microsatellite-stable colorectal cancer, who...
- The National Cancer Institute (NCI) awarded a $105,189 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Regents of the University of Minnesota to support research aimed at "Deciphering APOBEC Inhibition: Unraveling Structural Dynamics via Viral Protein and Nanobody Interactions." The project seeks to advance the structural understanding of the APOBEC3A and APOBEC3B enzymes, which play critical roles in both host defense and cancer mutagenesis....
- This Project Grant award of $352,275.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to develop a novel agent called MITOMET to target mitochondria in lung cancer cells with co-occurring KRAS and LKB1 mutations. The 5-year project, which began on January 1, 2025, seeks to assess the safety and efficacy of MITOMET in suppressing the malignant progression of lung tumors, determine its ability to modulate the tumor immune microenvironment, and...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $221,456.00 to the Regents of the University of Minnesota to develop and optimize a novel approach for enriching microbes from clinical cancer samples. The goal is to enable deep metaproteomic analysis and characterize the functional proteins contributed by microbes that influence the tumor microenvironment during cancer development. The project will pursue two specific...
- This Project Grant award of $420,400 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by the University of Texas MD Anderson Cancer Center to explore cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors in MTAP-loss tumor cells. The research aims to address the challenge of innate and acquired resistance observed in 40-60% and 20-30% of MTAP-loss cancer patients, respectively, when treated with these novel...
- This Project Grant award, worth $617,868.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Regents of the University of Minnesota. The funding supports an evaluation of a novel TRIKE-PACC molecule to amplify natural killer cell function in mesothelioma, a type of cancer. The research aims to improve health outcomes for military service members, veterans, and the broader public. The award commenced on July 15, 2024 and...
- This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,155,000.00 to the Regents of the University of Minnesota to evaluate prostate cancer patient natural killer cell function across racial backgrounds and address any functional disparities using tri-specific killer engagers. The research project will be conducted from June 1, 2025 through May 31, 2029 in Minneapolis, MN. As a prominent land-grant...